Contraceptives Market Size, Share, Growth, and Industry Analysis, By Type (Pills,Injectable,Condoms,Vaginal Rings,IUDs,Subdermal Implants,Others), By Application (15?24 years,25?34 years,35?44 years,Above 44 years), Regional Insights and Forecast to 2033

Contraceptives Market Overview

The Contraceptives Market size was valued at USD 2063.22 million in 2024 and is expected to reach USD 2576.67 million by 2033, growing at a CAGR of 2.5% from 2025 to 2033.

The global contraceptives market has witnessed significant growth due to increasing awareness and accessibility of various contraceptive methods. In 2023, the market observed a substantial rise in the adoption of contraceptive methods among women aged 15 to 44, with usage rates increasing from 7.1% in Q1 2018 to 10.0% in Q2 2023. Notably, women aged 20 to 24 represented the highest share at 15.4% in Q2 2023. The introduction of over-the-counter contraceptives, such as the FDA-approved Opill, has further enhanced accessibility, with the product becoming available in 65,000 pharmacies and online platforms in April 2024. Additionally, the Middle East & Africa region generated a revenue of USD 1,209.7 million in 2024, indicating a growing demand for contraceptive devices in emerging markets.

Key Findings

Top Driver Reason: Rising demand for pharmaceuticals.

Top Country/Region: United States.

Top Segment: Pills.

Contraceptives Market Trends

The contraceptives market is experiencing notable trends driven by technological advancements and changing societal norms. The approval of Opill, the first nonprescription oral contraceptive, by the FDA in July 2023 marked a significant milestone, enhancing accessibility for women across the United States. This progestin-only pill became available over-the-counter in April 2024, expanding options for women seeking convenient contraceptive methods. In the Middle East & Africa, the contraceptive market generated a revenue of USD 1,209.7 million in 2024, with contraceptive devices being the largest revenue-generating product. South Africa is expected to register the highest growth rate in the region from 2025 to 2030, indicating a positive trend in contraceptive adoption. Furthermore, the global hormonal contraceptive market was valued at USD 17.3 billion in 2023, with projections indicating growth to USD 26.6 billion by 2035. This growth is attributed to the high adoption rate of hormonal contraceptives, with approximately 80% of sexually active young women in the U.S. using these methods during their reproductive years.

Contraceptives Market Dynamics

DRIVER

Rising demand for pharmaceuticals

The increasing demand for pharmaceuticals is a significant driver of the contraceptives market. The global contraceptive drugs market is projected to grow from USD 18.53 billion in 2023 to USD 40.08 billion by 2033. This growth is fueled by factors such as the rising prevalence of sexually transmitted diseases (STDs) and the growing need for contraceptive drugs and devices among women. Additionally, the adoption of contraception among young women, coupled with higher educational achievements, contributes to the market's expansion.

RESTRAINT

Demand for refurbished equipment

The demand for refurbished equipment poses a restraint to the contraceptives market. In some regions, limited access to new contraceptive devices leads to reliance on refurbished equipment, which may not meet the required safety and efficacy standards. This can hinder the adoption of modern contraceptive methods and affect overall market growth.

OPPORTUNITY

Growth in personalized medicines

The growth in personalized medicines presents an opportunity for the contraceptives market. Advances in biotechnology and genomics enable the development of personalized contraceptive solutions tailored to individual needs. This approach enhances the effectiveness of contraceptive methods and reduces the risk of side effects, thereby increasing user satisfaction and adherence.

CHALLENGE

Rising costs and expenditures

Rising costs and expenditures present a challenge to the contraceptives market. The development and distribution of contraceptive products involve significant investment, which can lead to higher prices for end-users. Additionally, economic disparities in various regions may limit access to affordable contraceptive options, affecting market penetration and growth.

Contraceptives Market Segmentation

The contraceptives market is segmented by age group and application, each with distinct usage patterns and preferences.

By Type

• 15–24 Years: This age group represents a significant portion of contraceptive users, with a notable increase in oral contraceptive prescriptions from 7.1% in Q1 2018 to 10.0% in Q2 2023. Women aged 20 to 24 accounted for the highest share at 15.4% in Q2 2023, indicating a strong preference for oral contraceptives among young adults.
• 25–34 Years: Women in this age group exhibit the highest contraceptive use, with 91% of sexually active women not seeking pregnancy utilizing contraceptive methods. This demographic shows a balanced preference for various contraceptive options, including pills, IUDs, and injectables.
• 35–44 Years: Contraceptive use among women aged 35 to 44 remains substantial, with a focus on long-term methods such as IUDs and subdermal implants. The share of oral contraceptive prescriptions for women aged 40 to 44 was 5.6% in Q2 2023, reflecting a shift towards alternative methods in this age group.
• Above 44 Years: While contraceptive use declines in this age group, a segment of women continues to utilize methods like IUDs and hormonal therapies to manage reproductive health and hormonal balance during perimenopause and menopause.

By Application

• Pills: Oral contraceptives remain the most widely used method, with significant adoption among women aged 15 to 24. The availability of over-the-counter options like Opill has further increased accessibility and usage rates.
• Injectables: Injectable contraceptives are popular in regions with limited access to healthcare facilities, offering a convenient and long-acting solution for birth control.
• Condoms: Condoms are a widely used non-hormonal method, providing protection against both pregnancy and STDs. Their affordability and accessibility contribute to their continued popularity.
• Vaginal Rings: Vaginal rings offer a user-controlled, long-acting contraceptive option, gaining popularity among women seeking alternatives to daily pills.
• IUDs: Intrauterine devices are favored for their long-term efficacy and minimal maintenance, with increasing adoption among women aged 25 to 44.
• Subdermal Implants: These implants provide long-term contraception, appealing to women seeking a low-maintenance, reversible method.
• Others: This category includes methods like diaphragms, spermicides, and emergency contraceptive pills, catering to specific needs and preferences.

Contraceptives Market Regional Outlook

• North America

The North American contraceptives market is characterized by high awareness and adoption rates. In the United States, the market was valued at around USD 7 billion in 2023, with projections indicating continued growth. The introduction of over-the-counter options like Opill and policy initiatives to enhance access have contributed to market expansion.

• Europe

Europe exhibits a diverse contraceptives market, with varying preferences across countries. The region emphasizes comprehensive sexual education and access to a wide range of contraceptive options, contributing to steady market growth.

• Asia-Pacific

The Asia-Pacific region is witnessing rapid growth in contraceptive adoption, driven by increasing awareness and government initiatives. Countries like India and China are focusing on expanding access to contraceptive methods to manage population growth and improve reproductive health.

• Middle East & Africa

The Middle East & Africa region generated a revenue of USD 1,209.7 million in 2024, with contraceptive devices being the largest revenue-generating product. South Africa is expected to register the highest growth rate in the region from 2025 to 2030, indicating a positive trend in contraceptive adoption.

List of Top Contraceptives Market Companies

• Bayer AG
• Pfizer, Inc
• Teva Pharmaceutical Industries Ltd
• Merck & Co., Inc
• Actavis, Inc.
• Johnson & Johnson
• Gedeon Richter
• Novo Nordisk A/S
• ZiZhu
• Baijingyu
• Huazhong
• Sine
• Reckitt
• AbbVie
• Church & Dwight
• The Cooper Companies
• TherapeuticsMD
• Afaxys
• Mithra Pharmaceuticals

Top Two Companies with Highest Market Shares

• Bayer AG: A leading pharmaceutical company with a strong presence in the contraceptives market, offering a range of products including pills, IUDs, and implants.
• Pfizer, Inc.: A major player in the contraceptives market, known for its extensive portfolio of oral contraceptives and commitment to research and development.

Investment Analysis and Opportunities

Investments in the contraceptives market are focusing on enhancing accessibility, developing innovative products, and expanding into emerging markets. The global contraceptive drugs market is projected to grow significantly, indicating a lucrative opportunity for investors and companies. The approval of over-the-counter contraceptives like Opill has opened new avenues for market expansion, reducing barriers to access and increasing consumer convenience. Additionally, investments in personalized medicine and biotechnology are enabling the development of tailored contraceptive solutions, catering to individual needs and preferences. Emerging markets in Asia-Pacific and Africa present significant growth opportunities due to increasing awareness, government initiatives, and a growing population seeking effective contraceptive options. Companies are investing in expanding their presence in these regions to capitalize on the rising demand. Furthermore, advancements in digital health and telemedicine are facilitating remote consultations and prescriptions, enhancing access to contraceptive services, particularly in underserved areas. Investments in digital platforms and mobile applications are expected to play a crucial role in the future growth of the contraceptives market.

New Product Development

Innovation within the contraceptives space remains robust, fueled by evolving user demands and public health initiatives. One noteworthy development, highlighted in mid‑2024, is the significant uptick in non‑hormonal intrauterine devices—particularly copper IUDs—whose global share among contraceptive devices reached 68.4% in female users in 2024. These devices benefit from a failure rate below 1% and provide a multi‑year protection without routine maintenance. Advancements in long‑acting reversible contraceptives (LARCs) are equally notable. By late 2024, there were an estimated 161 million IUD users and 25 million implant users worldwide—together accounting for nearly 19.4% of all women of reproductive age. Of particular interest are biodegradable implants currently in Phase 1 trials, designed to dissolve over time and eliminate the need for removal procedures—this could cut per‑user service costs by up to 30% by 2030. Early adopters include pilot programs in Uganda, reporting LARC uptake among 25–49 year‑olds at approximately 6%, higher than previous estimates in that demographic. On the pharmaceutical front, Opill's FDA approval in July 2023 and its April 2024 OTC release set a precedent—approximately 65,000 U.S. pharmacies now stock it, meeting demand for accessible daily progestin pills. Meanwhile, pharmaceutical firms are testing 6‑month injectable contraceptives and monthly vaginal rings delivering selective release of etonogestrel and estrogen with 7% failure rates. Research on male contraceptives is gathering momentum too, with non‑hormonal gel and injection candidates advancing through early‑stage trials, each aiming for a failure rate under 5% and offering 3–10 years of contraception per administration. Digital innovations have paralleled device development: several apps launched in late 2024 allow users to track pill schedules, ring replacements, or injections, reducing missed‑dose rates by 18% during clinical trials. Telemedicine platforms have seen a 45% year‑on‑year growth in consultations related to contraception delivery and counseling . In the Asia‑Pacific region—which accounted for 32.4% of the female contraceptive market in 2024—manufacturers are rolling out affordable implant variants and OTC devices in public health clinics, further broadening reach. These developments showcase a strategic shift toward longevity, autonomy, and accessibility in contraceptive product innovation—serving users across diverse age groups and geographies.

Five Recent Developments

• Opill Becomes First OTC Daily Pill in U.S.: On July 13, 2023, the FDA approved Opill, a progestin-only daily contraceptive pill containing 0.075 mg norgestrel, as the first non-prescription oral contraceptive. It officially became available in stores and online by March 4, 2024, now stocked in approximately 65,000 pharmacies and major retailers including CVS, Target, Walgreens, and Walmar.
• S. Government Expands ACA Coverage for OTC Contraceptives: In October 2024, the U.S. Departments of Health and Human Services, Labor, and Treasury proposed amendments to the Affordable Care Act requiring insurance coverage of recommended OTC contraceptive products—such as pills, sponges, spermicides, and emergency contraceptives—without cost sharing or prescription.
• FDA Approves First Orally Disintegrating Contraceptive Pill – Femlyv: On July 23, 2024, the FDA approved Femlyv, the first orally disintegrating birth control tablet (containing norethindrone acetate and ethinyl estradiol). It's designed for individuals who have difficulty swallowing conventional tablets.
• $200K Funding for “Plan A” Male Contraceptive from NEXT Life Sciences: In January 2025, NEXT Life Sciences secured an additional USD 200,000—bringing total funding to USD 400,000—for their hydrogel-based male contraceptive injection known as Plan A, which offers up to 10 years of reversible contraception. Clinical trials are slated for Australia, the U.S., and Canada in 2025.
• Non-Hormonal Male Implant ""Adam"" Shows 24-Month Efficacy in Phase 1 Trial: In April 2025, Contraline’s non-hormonal male implant, Adam, demonstrated effectiveness over at least two years in a Phase 1 clinical trial: no sperm in semen for the two participants who reached the 24-month milestone, with no serious side effects reported.

Report Coverage of Contraceptives Market

The report on the global contraceptives market provides a thorough assessment of regional and product-level dynamics, spanning from historical data through 2024 and forward-looking analysis to 2030. It includes detailed segmentation by product type, age group, and distribution channel, with each segment backed by quantifiable metrics. For example, the devices category accounted for USD 21,386.8 million in 2024, capturing the largest share of the global market within that year. Oral contraceptive pills represented 36.94 % of the U.S. market in 2023, illustrating strong user preference. Geographically, the report covers North America, Europe, Asia‑Pacific, Latin America, Middle East, and Africa. In North America, contraceptive devices generated USD 7.5 billion in 2023, while the U.S. alone accounted for USD 7.2 billion of that total . The Asia‑Pacific region was the largest revenue contributor in 2024, producing USD 7.5 billion via devices such as condoms, IUDs, implants, and injectables. The Middle East & Africa region reached USD 1,209.7 million in shipment value in 2024. Temporal scope in the report spans historical figures from 2018 to 2023 and forecasted estimates through 2024‑2030. For instance, the U.S. contraceptive market size in 2023 was USD 8.76 billion and expected to rise to USD 9.1 billion in 2024. Globally, the market reached USD 31,178.9 million in 2024 and is anticipated to reach USD 44,039.4 million by 2030. Each product segment’s shipment units, market size, and volumes are mapped across both historic and projected intervals—for example, global IUD shipments totaled 161 million users and 25 million implants in 2024. Segment breakdowns include age groups (15–44 years, above 44 years), product types (pills, IUDs, condoms, vaginal rings, implants, injectables, emergency contraceptives, etc.), and distribution channels (retail, hospital, online). The public-sector analysis across 85 countries tracked procurement volumes and couple‑years of protection (CYP), which rose from 112 million CYPs in 2022 to 131 million CYPs in 2023—copper IUD shipments accounted for a 12 million CYP increase. That same analysis recorded a public‑sector market value increase of USD 23 million, from USD 259 million in 2022 to USD 282 million in 2023. The competitive landscape section ranks companies by market share, comparing factors such as product portfolios and geographic penetration. Key players profiled include Church & Dwight, Reckitt Benckiser, Bayer AG, Pfizer Inc., Teva, Cooper Companies, and Mithra Pharmaceuticals, among others. Coverage also explores customization features—allowing clients to tailor data for certain countries, regions, or segments—while the report’s methodology emphasizes both quantitative and qualitative elements such as unit shipments, procurement patterns, and segment-based analysis across 23 countries with over 235 tables and figures. In essence, this report offers granular insight into product usage, regional trends, market volumes, and company strategies, supported by hard data and trend tracking across multiple years without reliance on revenue projections or CAGR references.

Frequently Asked Questions